Sensitive and validated HPLC method for determination of paclitaxel in human serum

Indian Journal of Science and Technology

Volumn 2, Issue 5, 2009, Pages 52-54

  Rajender, G ^a   Narayanan, N G B ^a  

^a Research and Development Division   (India)

Author keywords

HPLC; Human blood sample; Paclitaxel; Serum

Indexed keywords

EID: 84906281817     PISSN: 09746846     EISSN: 09745645     Source Type: Journal    
DOI: 10.17485/ijst/2009/v2i5.16     Document Type: Article

References (11)

1. Heldman A Cheng L, Jenkins G, Heller P, Kim D, Ware M, Nater C, Hruban R, Rezai B, Abella B, Bunge K, Kinsella J, Sollott S, Lakatta E, Brinker J, Hunter W, and Froehlich J (2001) Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation. 103, 2289-95.
2. Kuhn J, Rizzo J, Chang S, Schold C, Spence A, Berger M, Robbins H, Metha M, Bozik M, Fulton D, Rector D and Prodos M (1997) Effect of anticinvulsants (ACs) on the phromacokinetics (PK) and metabolic profile of Paclitaxel. Am. Soc. Clin. Oncol. 16, 224a.
3. Kumar N (1981) Taxol-induced Polymerization of Purified Tubulin. J. Biological. Chem. 256, 10435-10441.
4. Nannan Panday VR, Meerum Terwot JM and Ten Bokkel Huinink WW (1998) The role of pro drug therapy in the treatment of cancer. Proc. Am. Soc. Clin. Oncol. 17, 742a.
5. Patton JF, Suzanne J, Fanthony G, Haimworth J, Willent N, Baker, Bechert J, Lacerna L and Howard Buris (2000) Weekly paclitaxel prolongated oral eniluracil/5-flurouracil: results of a phase-I combination study. Proc. Am. Soc. Clin. Oncol. 19, 746a.
6. Rinaldi, DA, Lormand N, Brierre J, Cole J, Stagg P, Fontenot F, Buller E and Rainer J (2000) A phase 1 trial of gemcitabine (GEM) and paclitaxel (PAc) in patients with advanced solid tumors, administered every 21 days (LOA-2). Proc. Am. Soc. Clin. Oncol. 19, 848a.
7. Schellens JHM, Meeru JM, Bokke HWW, Rosing H, Tellingen O, Swart M, Duchin KL and Beijner JH (1998) Cyclosporin A (CsA) strongly enhances oral bioavailability of paclitaxel (Pac) in cancer patients. Pro. Am. Soc. Clin. Oncol. 17, 717a.
8. Schwartz GK, Kaubish A, Saltz L and Lison D (2000) Phase 1 trial of sequential paclitaxel and the cyclin dependent kinase inhibitor flavopiridol. Proc. Am. Soc. Clin. Oncol. 18, 160a.
9. Sharma A, Conway WD and Staudinger RM (1994) Reverse-phase highperformance liquid chromatographic determination of taxol in mouse plasma. J. Chromatogr. 655, 315-319.
10. Sparreboom A and Van Tellingen O (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anti Cancer Drugs. 8, 1-17.
11. Wani M, Taylor H, Wall M, Coggon P and McPhail A (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J.Am. Chem. Soc. 93, 2325-2327.